Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00302744 · ClinicalTrials.gov registry record · Phase 1
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
A Phase 1 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00302744 is a Phase 1 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00302744, a Phase 1 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
Interventions
- DIAGNOSTIC_TEST MRI
- OTHER Niacin
- DRUG Psilocybin (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00302744
The ClinicalTrials.gov registry entry for NCT00302744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MRI is the first listed.
NCT00302744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00302744 about?
NCT00302744 is a clinical study titled "Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety". Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
What is the current status of trial NCT00302744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00302744?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Niacin (OTHER), Psilocybin (drug) (DRUG).
Who is sponsoring clinical trial NCT00302744?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.